Mouse anti-VEGF [+Biotin]
Mouse anti-VEGF Biotinylated Antibody, 50 ug
ELISA (recommended work dilution= 6.25 µg/ml ), Western Blotting (recommended work dilution= 1:2000 ), (see image) Immunodetection Analysis: Representative blot from a previous lot. Lane 1, recombinant protein VEGF, Lane 2, protein marker. The membrane blot was probed with antiVEGF primary antibody ( 0.5 µg/ ml ). Proteins were visualized using a donkey anti-mouse secondary antibody conjugated to IRDye 800CW detection system.
Immunogen was recombinant protein derived from VEGF. This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with the immunogen. The IgG fraction of tissue culture supernatant was purified by Protein G/A affinity chromatography.
A separate vial of dilution buffer is provided for reconstitution. The antibody is supplied lyophilized, originally containing PBS, without preservative stabilizers (e.g. sodium azide). The final amount is indicated on the shipping vial.
Vascular endothelial growth factor (VEGF) is a member of the PDGF/VEGF growth factor family, produced by cells that stimulate the growth of new blood vessels. VEGF family includes VEGF-A, B, C, and D isoforms. VEGF-A was called VEGF before other isoforms were discovered. VEGF plays an important role in creating new blood vessels, inducing angiogenesis, vasculogenesis and endothelial cell growth, inhibiting apoptosis, mediating increased vascular permeability, promoting cell migration, etc. VEGF members stimulate cellular responses through binding to tyrosine kinase receptors (VEGFRs) on the cell surface.
The antibody is stable for at least 1 year from the date of receipt when stored at -20°C to -70°C. Reconstituted antibody can also be aliquotted and stored at 4°C for 1 month or at -20°C to -70°C in a manual defrost freezer for many months without detectable loss activity. Please avoid freeze-thaw cycles.
The mouse anti-human VEGF antibody specifically detects targets derived from human recombinant protein at various concentrations. Cross reactivity with mouse and rat are expected from sequence similarity.
- Holmes K, et al. (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal. 19 (10): 20032012.
- Bergers G, Hanahan D (2008). Modes of resistance to antiangiogenic therapy. Nat. Rev. Cancer 8 (8): 592603.
- Rosenfeld PJ, et al. (2006). Ranibizumab for neovascular agerelated macular degeneration. New Engl J Med. 355 (14): 14191431.